Therapeutic options for recurrent malignant glioma

详细信息    查看全文

• 作者：Maximilian Niyazi^a ; ^{maximilian.niyazi@med.uni-muenchen.de} ; Axel Siefert^a ; ^{axel.siefert@med.uni-muenchen.de} ; Silke Birgit Schwarz^a ; ^{silke.schwarz@med.uni-muenchen.de} ; Ute Ganswindt^a ; ^{ute.ganswindt@med.uni-muenchen.de} ; Friedrich-Wilhelm Kreth^b ; ^{friedrich-wilhelm.kreth@med.uni-muenchen.de} ; Jö ; rg-Christian Tonn^b ; ^{joerg.christian.tonn@med.uni-muenchen.de} ; Claus Belka^a ; ^{claus.belka@med.uni-muenchen.de}
• 关键词：Malignant glioma ; Relapse ; Radiotherapy ; Temozolomide ; Bevacizumab
• 刊名：Radiotherapy and Oncology
• 出版年：2011
• 出版时间：January 2011
• 年：2011
• 卷：98
• 期：1
• 页码：1-14
• 全文大小：279 K

文摘

Background and purpose: Despite the given advances in neuro-oncology most patients with high grade malignant glioma ultimately fail locally or locoregionally. In parallel with improvements of initial treatment options, several salvage strategies have been elucidated and already entered clinical practice. Aim of this article is to review the current status of salvage strategies in recurrent high grade glioma. Material and methods: Using the following MESH headings and combinations of these terms the pubmed database was searched: “Glioma”, “Recurrence”, “Neoplasm Recurrence, Local”, “Radiosurgery”, “Brachytherapy”, “Neurosurgical Procedures” and “Drug Therapy”. For citation crosscheck the ISI web of science database was used employing the same search terms. In parallel, the abstracts of ASCO 2008–2009 were analyzed accordingly. Results: Currently the following options for salvage entered clinical practice: re-resection, re-irradiation (stereotactic radiosurgery, (hypo-)fractionated (stereotactic) radiotherapy, interstitial brachytherapy) or single/poly-chemotherapy schedules including new dose-intensified or alternative treatment protocols employing targeted drugs. Re-operation is associated with high morbidity and mortality, however, is an option in a highly selected patient cohort. Since toxicity has been overestimated, re-irradiation is an increasingly used option with precise fractionated radiotherapy being the most optimal technique. On average, time to secondary progression is in the range of several months. Conventional chemotherapy regimens also improve time to secondary progression; however the efficacy is only modest and treatment-related toxicities like myelo-suppression occur very frequently. Molecular targeted agents/kinases are undergoing clinical testing; however no final recommendations can be made. Conclusions: Currently, several re-treatment options with only modest efficacy exist. The relative value of each approach compared to other options is unknown as well as it remains open which sequence of modalities should be chosen.